Piribedil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Piribedil
Accession Number
DB12478
Description

Piribedil has been investigated in Parkinson's Disease.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 298.346
Monoisotopic: 298.142975836
Chemical Formula
C16H18N4O2
Synonyms
Not Available
External IDs
  • ET-495
  • EU-4200

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UDopamine D2 receptorNot AvailableHumans
UDopamine D3 receptorNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineThe therapeutic efficacy of Piribedil can be decreased when used in combination with Acetophenazine.
AmisulprideThe therapeutic efficacy of Piribedil can be decreased when used in combination with Amisulpride.
AmoxapineThe therapeutic efficacy of Piribedil can be decreased when used in combination with Amoxapine.
ApomorphineThe risk or severity of adverse effects can be decreased when Apomorphine is combined with Piribedil.
AripiprazoleThe risk or severity of adverse effects can be decreased when Aripiprazole is combined with Piribedil.
AsenapineThe therapeutic efficacy of Piribedil can be decreased when used in combination with Asenapine.
BenperidolThe therapeutic efficacy of Piribedil can be decreased when used in combination with Benperidol.
BrexpiprazoleThe risk or severity of adverse effects can be decreased when Brexpiprazole is combined with Piribedil.
BromocriptineThe risk or severity of adverse effects can be decreased when Bromocriptine is combined with Piribedil.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Piribedil.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More

Categories

ATC Codes
N04BC08 — Piribedil
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Benzodioxoles / Dialkylarylamines / N-alkylpiperazines / Aralkylamines / Aminopyrimidines and derivatives / Benzenoids / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Azacyclic compounds
show 3 more
Substituents
Acetal / Amine / Aminopyrimidine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzodioxole / Dialkylarylamine / Heteroaromatic compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
DO22K1PRDJ
CAS number
3605-01-4
InChI Key
OQDPVLVUJFGPGQ-UHFFFAOYSA-N
InChI
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2
IUPAC Name
2-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}pyrimidine
SMILES
C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1

References

General References
  1. FDA Thailand Product Information: Trivastal (piribedil) extended-release tablets [Link]
  2. TITCK Product Information: Trivatal (piribedil) extended-release tablets [Link]
PubChem Compound
4850
PubChem Substance
347828716
ChemSpider
4684
BindingDB
85092
RxNav
8353
ChEBI
92833
ChEMBL
CHEMBL1371770
ZINC
ZINC000019537374
Wikipedia
Piribedil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentIdiopathic Parkinson's Disease1
Not AvailableCompletedNot AvailableParkinson's Disease (PD)3
Not AvailableCompletedTreatmentTinnitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular3 mg/1mL
Tablet, extended releaseOral50 mg
Tablet, film coated, extended releaseOral50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.57 mg/mLALOGPS
logP1.56ALOGPS
logP2.03ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)6.53ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area50.72 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity83.53 m3·mol-1ChemAxon
Polarizability31.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-1930000000-45b06a981c7ebf1054da

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Millan MJ, Girardon S, Monneyron S, Dekeyne A: Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. [PubMed:10728880]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Millan MJ, Girardon S, Monneyron S, Dekeyne A: Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. [PubMed:10728880]

Drug created on October 20, 2016 16:32 / Updated on October 24, 2020 01:30

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates